[144] ALUMIS INC. SEC Filing
This article details an SEC Form 144 filing by ALUMIS INC. (ALMS), indicating a proposed sale of 5,000 shares of common stock with an aggregate market value of $140,000, acquired through a stock option exercise. The filing, accepted by the SEC on July 6, 2026, also provides general information about Form 144 requirements and the company's recent news and financial data.
Price to sales forward of Alumis Inc. – NASDAQ:ALMS
The article provides a snapshot of the "Price to sales forward" financial metric for Alumis Inc. (NASDAQ:ALMS) as presented on TradingView. It indicates that the market was closed at the time of viewing, with no trades having occurred for this specific metric. The page appears to be a financial data presentation and does not contain analytical text or further details.
Price to book forward of Alumis Inc. – NASDAQ:ALMS
This article provides the "Price to book forward" metric for Alumis Inc. (NASDAQ: ALMS) from TradingView. The page displays the current value, change, and percentage change for this financial indicator, noting that the market is closed and no trades have occurred for ALMS.
Alumis (ALMS) director Lynn Tetrault receives RSU and stock option awards
Alumis Inc. director Lynn A. Tetrault has been granted 3,553 restricted stock units (RSUs) and stock options for 15,528 shares with an exercise price of $28.14. Both awards are set to vest on the first anniversary of the grant date, or by the company's 2027 annual stockholder meeting, contingent on her continuous service. The awards also feature full vesting upon a qualifying change in control, provided service is maintained.
Price to earnings forward of Alumis Inc. – NASDAQ:ALMS
The article provides financial information for Alumis Inc. (NASDAQ:ALMS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of viewing. The content is primarily a listing of financial data access points and general website navigation.
Director at ALUMIS (NASDAQ: ALMS) receives RSU and option grants
ALUMIS director Yao Zhengbin received grants of 3,553 restricted stock units (RSUs) and stock options for 15,528 shares, with an exercise price of $28.14 per share, expiring in 2036. These equity compensation awards, detailed in a Form 4 filing, were not open-market trades. Both the RSUs and options vest on their first anniversary, or by the company's 2027 annual stockholder meeting, subject to continuous service.
Alumis Inc. Files Form 8-K: Key Details on Common Stock (ALMS) and Nasdaq Listing
Alumis Inc. (Nasdaq: ALMS) recently filed a Form 8-K detailing the results of its 2026 Annual Meeting of Stockholders held on June 30, 2026. Shareholders re-elected three Class II directors and ratified PricewaterhouseCoopers LLP as the independent auditor, signaling stability and confidence in the company's governance and financial reporting. The company, an Emerging Growth Company listed on The Nasdaq Global Select Market, also confirmed its decision not to use the extended transition period for new accounting standards, potentially impacting future financial interpretations.
Form 4 Alumis Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for Alumis Inc. on July 2nd, as published by Investing.com. It is a brief administrative notice regarding SEC filings for the company ALMS. The article provides the filing date and mentions the company's stock symbol.
Form 13D/A Alumis Inc. For: 2 July By Investing.com
This article announces the filing of a Form 13D/A for Alumis Inc. on July 2nd. It provides a brief update on a regulatory filing related to the company.
[Form 4] ALUMIS INC. Insider Trading Activity
ALUMIS INC. director Sapna Srivastava received equity-based compensation as reported in a Form 4 filing. This compensation included 3,553 shares of common stock from restricted stock units and options for 15,528 shares of common stock with an exercise price of $28.14. Both the RSUs and stock options will vest on the first anniversary of the grant date, or fully by the 2027 annual stockholder meeting, contingent on continuous service and immediate vesting upon a Change in Control.
Alumis Shareholders Reelect Directors and Ratify Auditor
Alumis Inc. shareholders reelected three Class II directors, James B. Tananbaum, Lynn Tetrault, and Zhengbin (Bing) Yao, to their board during the 2026 Annual Meeting, ensuring leadership continuity. Additionally, stockholders ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026, confirming confidence in the company's financial oversight. Despite weak financial performance, the company's technicals are strong, and recent corporate events show encouraging Phase 3 data.
[8-K] ALUMIS INC. Reports Material Event
Alumis Inc. filed an 8-K report detailing the results of its 2026 Annual Meeting of Stockholders held on June 30, 2026. Shareholders elected new Class II directors James B. Tananbaum, Lynn Tetrault, and Zhengbin (Bing) Yao to serve until the 2029 Annual Meeting and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. The filing includes detailed voting results for each proposal.
Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS
This article provides a financial metric for Alumis Inc. (NASDAQ: ALMS), focusing on its enterprise value to revenue forward. The content is primarily a listing of financial and market data, with specific details related to the company's valuation. It appears to be a snapshot from a financial data platform.
Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS
This article provides the enterprise value to EBITDA forward for Alumis Inc. (NASDAQ: ALMS). It also lists various financial data providers and legal disclaimers regarding market and reference data copyrights. The core content is very limited, primarily stating the financial metric for Alumis Inc.
Stifel and Guggenheim Stay Bullish on Alumis (ALMS)
Stifel and Guggenheim have reiterated their bullish stance on Alumis Inc. (ALMS), with a consensus Buy rating and a 12-month median price target of $39.50, indicating potential upside. Stifel maintained a $44 price target after positive Phase 3 data for envudeucitinib, while Guggenheim increased its target to $34 following strong Q1 earnings and clinical trial updates. Alumis is a late-stage biopharma company focusing on targeted therapies for immune-mediated diseases and expects to submit its New Drug Application in Q4 2026.
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark
Alumis Inc. (NasdaqGS: ALMS) has been added to the Russell 2500 Growth Benchmark, reflecting its growth potential and recent changes in index composition. This follows other significant index adjustments on June 29th, where Alumis was also added to the Russell 2000 Growth and Russell 3000E Growth benchmarks, while being dropped from several value and microcap indices. These changes highlight a reclassification of the company's investment profile.
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index
Alumis Inc. (NasdaqGS:ALMS) has been removed from the Russell Microcap Value Benchmark Index as of June 29, 2026. This news comes alongside several other index adjustments for Alumis on the same date, including additions to growth benchmarks and removals from other value and microcap indices. Investors are keeping a close watch on these index rebalancings and the impact on Alumis, a biopharmaceutical company focused on immune-mediated diseases.
Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation
Alumis Inc. (NASDAQ: ALMS) has released an updated corporate presentation for June 2026, furnishing it with the SEC via an 8-K filing. This presentation, available on the company's website, provides an overview for investors and analysts, highlighting the significant market opportunity for TYK2 molecules, particularly its lead candidates Envudeucitinib and A-005. Key anticipated milestones for 2026 include additional psoriasis data, an NDA filing for envudeucitinib, and topline Phase 2b SLE data, underscoring the company's strategic focus on immune-mediated diseases.
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark
Alumis Inc. (NasdaqGS: ALMS) has been added to the Russell 2000 Growth Benchmark, as announced by S&P Capital IQ on June 29, 2026, at 07:33 am EDT. This news comes alongside other recent index adjustments, including being dropped from the Russell 2000 Value Benchmark and added to the Russell 3000E Growth Benchmark. Alumis Inc. is a biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases.
Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed
Alumis Inc. (ALMS) saw its stock rise by 7.3% following its reclassification into several Russell growth indices, including the Russell 2000 Growth, 2500 Growth, and 3000 Growth. This shift redefines Alumis's investment narrative from value/microcap to growth, potentially impacting index-driven ownership and liquidity. However, the reclassification does not alter the company's fundamental risks, such as ongoing cash burn, a "going concern" flag from its auditor, and potential equity raises.
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55
Oppenheimer has reiterated its Buy rating for Alumis (ALMS.US) and maintained its target price at $55. This indicates continued confidence from the firm in the company's prospects.
Alumis Inc. Actuals & Estimates (BOATS:ALMS)
This article provides an overview of Alumis Inc. (ALMS) stock, including financial actuals and estimates, analyst forecasts, historical price data, and upcoming earnings information. It details the company's financial performance, such as recent earnings and revenue, and states that ALMS does not pay dividends. The article also provides key financial metrics like EBITDA and employee count.
ALMS Forecast — Price Target — Prediction for 2027
Alumis Inc. (ALMS) has a price target of $40.10, with analysts' future price predictions ranging from $25.00 to $55.00. The company's stock reached an all-time high of $30.14 on Feb 23, 2026, and an all-time low of $2.90 on June 30, 2025. Alumis Inc. does not pay dividends and has 224 employees as of June 26, 2026.
Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC
This document is a statement of changes in beneficial ownership of securities for Alumis, specifically involving a 10% owner, Foresite Capital Management VI LLC. Such statements are routinely filed with regulatory bodies to disclose significant changes in ownership by major shareholders.
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Alumis Inc (ALMS) currently has an earnings forecast score of 9.09, placing it favorably within the Biotechnology & Medical Research industry. Analysts have assigned an average price target of $18.00 for ALMS, with a majority recommending a "Buy" rating. The company's expected revenue for the next quarter is $4.02 million, with an anticipated EPS of -$0.72.
Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Alumis Inc (ALMS), detailing its business segments, regional revenue, and profit contribution. It notes that significant financial data for FY2025, including quarterly breakdowns, has not yet been disclosed by the company. The currently available regional data indicates revenue of $24.05 million for the United States, representing 0.00% proportion.
Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06
Alumis Inc (ALMS) experienced a 10.3% stock surge, closing at $23.06, driven by positive market sentiment and investor interest in its biotechnology therapies. Despite a low GF Score™ of 14/100 due to profitability concerns, the company exhibits strong financial stability with an Altman Z-Score of 12.84. Insiders have shown confidence with 15 buy transactions and no sells in the past year, though its high price-to-sales ratio of 266.19 suggests a premium valuation.
Alumis Shares Surge 16% as Traders Eye New Drug Move
Alumis Inc. (ALMS) shares jumped 15.55% to $24.15 on high volume as traders anticipate key clinical and regulatory milestones for its main drug, envudeucitinib. The late-stage biopharma company, which currently operates at a loss, is expecting Phase 2b LUMUS lupus data in Q3 2026 and plans a psoriasis NDA submission in Q4 2026. While analysts are largely bullish, the stock remains high-risk due to its lack of approved products and significant net losses, with its valuation largely dependent on successful trial results and FDA approval.
Alumis | SCHEDULE 13D/A: Others
This article consists solely of the word "Document," indicating it is likely a placeholder or a very brief record of a filing or piece of content. Without additional information, it's impossible to provide further context or detail.
Has Alumis's Envudeucitinib Redefined Psoriasis Treatment
Alumis's envudeucitinib, an oral TYK2 inhibitor, has shown strong Phase 3 results for plaque psoriasis, demonstrating high skin clearance rates and quality of life improvements. Its differentiated profile, including superior efficacy to apremilast and maximal 24-hour TYK2 inhibition, positions it as a potential leader in the oral psoriasis market. Upcoming catalysts include an FDA NDA submission in 2H 2026 and data for systemic lupus erythematosus in 3Q 2026, which could significantly increase its value and market reach.
ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS)
This article provides a stock chart for ALUMIS INC (NASDAQ: ALMS) from ChartMill.com. It shows the current stock price as 21.6 USD, indicating a 0.93% increase at market close on May 29, 2026. The article highlights various financial analysis tools available on the ChartMill platform.
Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares
Alumis Inc.'s Chief Medical Officer, Jorn Drappa, exercised stock options to acquire a total of 26,852 shares of common stock. These exercises, reported on May 22, 2026, involved two blocks of shares at strike prices of $5.06 and $8.84 per share. No open-market purchases or sales were included in this Form 4 filing, indicating an increase in Drappa's common stock holdings from option conversion.
10 Under-the-Radar Stocks with Massive Upside for 2026
This article highlights several under-the-radar stocks with massive upside potential for 2026, focusing on Alumis Inc. (NASDAQ:ALMS) as an example. Alumis Inc. has a 79.4% analyst consensus upside and has received multiple price target increases following positive Q1 results and advancements in its envudeucitinib pipeline. The company is on track for an NDA submission in Q4 2026 and a pivotal Phase 2b SLE topline readout in Q3 2026.
TOWERVIEW LLC's Alumis Inc(ALMS) Holding History
This article details TOWERVIEW LLC's holding history in Alumis Inc (ALMS). As of March 31, 2026, TOWERVIEW LLC holds 222,294 shares valued at $4.90 million, representing 3.16% of their portfolio. The firm has made 5 purchases and 1 sale of ALMS shares since Q2 2024, resulting in an estimated gain of $5.67 million, or 99.14%.
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors
Alumis Inc. recently reported Q1 2026 results with a significant revenue drop from US$17.39 million to US$1.74 million but a narrowed net loss of US$93.05 million, down from US$98.96 million. Despite the revenue slide, the company reduced its basic loss per share to US$0.74 from US$1.82. The article emphasizes that Alumis remains a clinical-stage company with significant funding risks, and its investment narrative hinges on the success of its TYK2 pipeline, especially with upcoming regulatory and clinical milestones in late 2026.
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors
Alumis Inc. recently reported significantly reduced Q1 2026 revenue of US$1.74 million, down from US$17.39 million, but also narrowed its net loss per share to US$0.74 from US$1.82. Despite the improved per-share loss, the company remains a clinical-stage entity with substantial cash consumption, and investors are focused on regulatory milestones, funding risks, and execution around its TYK2 pipeline. Analysts' fair value estimates for ALMS vary widely, underscoring the uncertainty and the importance of evaluating funding and pipeline progress.
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS
This article provides an overview of analyst ratings and price targets for Alumis Inc. (NASDAQ:ALMS). Based on 12 analysts, Alumis has a consensus price target of $36.73, with a high of $55 and a low of $14. The most recent analyst ratings suggest an implied 89.22% upside for the company.
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40
Chardan Capital has reiterated its Buy rating for Alumis (ALMS.US) and increased its target price to $40. This revision suggests a strong outlook from the firm regarding Alumis's future performance.
ALMS Maintained by Chardan Capital -- Price Target Raised to $40
Chardan Capital analyst Janani Sundararajan has reaffirmed a 'Buy' rating for Alumis (ALMS) and increased the price target to $40.00 from $38.00, reflecting confidence in the company's growth potential despite its low GF Score™ of 14/100. Alumis, a clinical-stage biopharmaceutical company with a market cap of $2.70 billion, focuses on developing innovative therapies, particularly two Tyrosine Kinase 2 (TYK2) inhibitors. While the stock's current price of $21.15 suggests potential upside based on analyst expectations, investors are advised to consider the company's low profitability rank and overall financial health.
Alumis price target raised to $40 from $38 at Chardan
Chardan has increased its price target for Alumis (ALMS) to $40 from $38, maintaining a Buy rating on the shares. This adjustment reflects updated pricing assumptions for envudeucitinib, minor changes in psoriasis penetration, and revised financial data following the company's first-quarter results and business update. Other analysts from Morgan Stanley, Wells Fargo, and Guggenheim also raised their price targets for Alumis, while H.C. Wainwright downgraded the stock to Neutral.
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones
Alumis (ALMS) stock is under scrutiny after reporting positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib but also weaker Q1 2026 revenue. Despite recent short-term pullbacks, the stock has shown strong long-term momentum. The article questions whether Alumis is undervalued after the recent data or if its future growth is already priced in, noting its P/B ratio of 5.1x suggests it is overvalued compared to industry averages and peers.
[ARS] ALUMIS INC. SEC Filing
This article reports on an ARS SEC filing by Alumis Inc. (ALMS) on May 18, 2026, at 04:29 PM. The filing is categorized with low impact and neutral sentiment. The article also provides recent news and SEC filings related to Alumis Inc., along with key stock data.
[DEF 14A] ALUMIS INC. Definitive Proxy Statement
Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The document details board composition, governance policies, executive and director compensation, and related person transactions, with a record date of May 5, 2026, for voting eligibility.
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026
Cormorant Asset Management has acquired 313,645 shares of Alumis during Q1 2026, investing $7.84 million in the biotechnology company. This investment increased Cormorant's stake value in Alumis by $51.52 million and represents 4.37% of its 13F assets. Alumis shares have surged 400% over the past year, driven by strong clinical trial data for its autoimmune and neuroinflammatory disorder therapies, with a New Drug Application expected in Q4 2026.
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?
Alumis Inc. (ALMS) reported Q1 2026 results with a net loss of US$93.05 million, but highlighted strong Phase 3 data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis. The company plans a New Drug Application in late 2026 for envudeucitinib and anticipates pivotal systemic lupus erythematosus data in Q3 2026, positioning the drug as a central asset. Investors are encouraged to focus on envudeucitinib's potential as a platform asset rather than current financials, with planned milestones expected to reshape the company's risk and reward profile.
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?
Alumis Inc. reported Q1 2026 losses and declining revenue, despite strong Phase 3 data for its oral TYK2 inhibitor, envudeucitinib. The company plans a New Drug Application for envudeucitinib in late 2026 for psoriasis and anticipates data for systemic lupus erythematosus, making this drug central to its strategy. Investors need to evaluate if they believe in envudeucitinib as a platform asset, considering the company's current financial losses and the concentration of risk in this single program.
Alumis (Nasdaq:ALMS) - Aktienanalyse
Alumis Inc. (Nasdaq:ALMS) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for autoimmune diseases. The company's stock is currently trading at US$22.04, with analysts estimating a fair value of US$40.1, indicating it is undervalued. Recent news highlights positive Phase 3 data for its psoriasis drug envudeucitinib, with plans for an NDA submission in Q4 2026, and potential pivotal Phase 2b data for systemic lupus erythematosus in Q3 2026.
HC Wainwright & Co. downgrades Alumis (ALMS)
This article reports that HC Wainwright & Co. has downgraded its rating for Alumis (ALMS). The specific details or reasons for the downgrade are not provided within the given content.
Stifel reiterates Alumis stock rating on psoriasis trial data
Stifel maintained a Buy rating and a $44.00 price target for Alumis Inc (ALMS) after the company's first-quarter 2026 update and positive Phase 3 data for its TYK2 inhibitor, envudeucitinib, in psoriasis. The firm highlighted that the data for envudeucitinib were comparable to or better than competitor drugs, and anticipates the upcoming Phase 2b data in systemic lupus erythematosus in Q3 2026 as a key catalyst. Other analysts from Guggenheim, H.C. Wainwright, Raymond James, and Leerink Partners also reiterated positive ratings based on the strong clinical trial results.
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This article details the top five analyst downgrades on Friday, May 15, 2026. Alumis Inc. (NASDAQ: ALMS) saw its rating cut from Buy to Neutral, while Tango Therapeutics (NASDAQ: TNGX), Viking Holdings (NYSE: VIK), Aardvark Therapeutics (NASDAQ: AARD), and A.O. Smith Corp (NYSE: AOS) also received downgrades from various analysts. The article provides the new ratings, price targets, and closing prices for each mentioned stock.
